Slides
Page 1
Clever Culture Systems ASX: CC5 1 AI-powered microbiology Revolutionising microbial quality control in pharmaceutical manufacturing Brent Barnes, CEO and Managing Director February 2026 ASX: CC5 For personal use only
Page 2
Disclaimer Clever Culture Systems ASX: CC5 2 This document contains certain forward -looking statements that involve risks and uncertainties. Although we believe that the exp ectations reflected in the forward -looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on any forward -looking statements. Actual results could differ materially from those anticipated in these forward -looking statements due to many important factors, risk and uncertainties including, without limitation, risks associated with estimating potential quantity and timing of sales, risks associated with medical device development and manufacture, risks inherent in the extensive regulatory approval process es mandated by regulatory authorities, delays in clinical trials, future capital needs, general economic uncertainly and other risks detailed from time to time in the Comp any’s announcements to the ASX. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages. All reasonable efforts have been made to provide accurate information, but the Company does not undertake any obligation to r elease publicly any revisions to any “forward -looking statement” to reflect events or circumstances after the date of this presentation, except as may be required under applicable laws. Recipients should make their own enquiries in relation to any investment decisions from a licensed investment advisor. NOT AN OFFER FOR SECURITIES This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An inve stor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before mak ing an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial si tuation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances. UNITED STATES The Company’s securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Secu rities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company’s securities may not be offered or sold, directly or indire ctly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be dist ributed within the United States or to any person in the United States OTHER JURISDICTIONS This Presentation may only be accessed in other jurisdictions where it is legal to do so. For personal use only
Page 3
Clever Culture Systems ASX: CC5 3 APAS® Independence setting new standard in high-growth pharmaceutical QC automation market Financial stability: High margin ARR >$1m, cashflow positive1, no debt Commercial delivery tailwinds Industry leaders backing APAS® technology with global adoption AstraZeneca, Bristol Myers Squibb, Pfizer, Novo Nordisk, Boehringer Ingelheim, Thermo Fisher (Patheon) $3.1m cash, known cash inflows of $1.9m over next 2 quarters at 31-Dec-25 FY25 maiden profit $1.7m, driven by product sales of $6.6m Q2 FY26 launch of contact plates expands APAS® utility and increases TAM Growing recurring revenue exceeding $1m, reported Q2 FY26 Snapshot 18-month financial stability Outlook underpinned by good science, tech, customers AstraZeneca with 11 APAS® instruments purchased, rolled out across global sites New data presented by industry leaders – APAS® becoming the new environmental monitoring standard 1. First Half FY26 cashflows from operating activitiesFor personal use only
Page 4
Clever Culture Systems ASX: CC5 4 High cost of failure Up to US$1bn lost revenue 1 Failed results in pharmaceutical manufacturing can lead to substantial revenue losses. Catastrophic impact is patient death Regulatory scrutiny 116% regulatory increase 2 Rise in regulatory observations to drug establishments creates compliance challenges Inefficient Up to 98% zero growth plates 3 Millions of plates reviewed annually, majority of plates have no growth yet require dual analyst verification, wasting resources Incorrect results costlyMillions of culture plates are manually read and reported annually during pharmaceutical manufacturing Problem 1. www.researchandmarkets.com, Global Pharmarcetuicals Market Report 2021: Covid-19 Impact and Recovery to 2030. 2. https://www.fda.gov/inspections-compliance-enforcement-and-criminal- investigations/inspection-references/inspection-observations 3. https://www.cleverculturesystems.com/scientific-library/apas-pharmaqc-ai-culture-plate- reading For personal use only
Page 5
Clever Culture Systems. ASX: CC5 5 Environmental monitoring today Mandatory process in every pharmaceutical manufacturing facility globally Cleanrooms (pharmaceutical manufacturing) Culture plate reading, reporting. Result to release pharmaceutical product Culture plates Growth detected ➔ Batch held ➔ Investigation No Growth ➔ Batch release Critical decision point Environmental monitoring Incubation (3-7 days) Workflow For personal use only
Page 6
Clever Culture Systems. ASX: CC5 6 Cutting edge AI technology Machine learning for microbiology applications Demonstrated performance Extensive scientific data, faster than microbiologist Improved data integrity Automatic data trails and audit reports Easy integration and user operation Simple plug and play technology Digital disruption Solution: APAS Automated Plate Assessment System Solution For personal use only
Page 7
Clever Culture Systems. ASX: CC5 7 Environmental monitoring with APAS Mandatory process in every pharmaceutical manufacturing facility globally Cleanrooms (pharmaceutical manufacturing) Culture plates Critical decision point Environmental monitoring Incubation (3-7 days) Growth detected ~2-10% reviewed manually No Growth >90% ➔ Batch release automatically Automated culture plate reading Workflow For personal use only
Page 8
Clever Culture Systems. ASX: CC5 8 Up to AU$1.5m revenue per APAS Independence sale1 Includes up-front Capex and Annual Recurring Revenue (ARR) streams 1. Typical revenue over 7 years (expected life of instrument) 2. Third-party service provider / distributor expected to provide service Product / Service Description Revenue Model Approx. Split APAS® Independence Laboratory Instrumentation Upfront Capex (inc. financing options) 40% APAS Apps® AI Software Licence ARR 40% APAS Service2 Support and maintenance services ARR 15% Implementation Services Instrument connectivity, technical data and validation support One-off 5% Revenue For personal use only
Page 9
Clever Culture Systems. ASX: CC5 9 AU$2.8B TAM2 Total Addressable Market for aseptic manufacturing microbiology testing. Pharma companies are investing in expanding manufacturing facilities and automation 14 of Top 203 Sales pipeline includes largest pharmaceutical manufacturers globally. Opportunity for multi -instrument sales, establishes industry credibility. >40 qualified leads Sales momentum building. Qualified opportunities represent ~$75 million in upfront sales and $15 million per annum in recurring revenues. 4 Opportunity 1. MarketsandMarkets (www.marketsandmarkets.com) - Lab Automation Market: Growth, Size, Share and Trends 2. Global Pharmaceuticals & Medicine Manufacturing; IBISWorld Industry Report + internal company analysis 3. Top 20 Pharma based on annual revenue 4. Sales Pipeline Value estimated on potential number of APAS instruments across current active customers Growing Global Laboratory Automation Market – Forecast to grow at 7.2% over next 5 years1 For personal use only
Page 10
Clever Culture Systems ASX: CC5 10 AstraZeneca Case Study Enterprise customer – Standardisation across multiple global sites 11 instruments purchased and installed • Multiple global manufacturing locations • Advocates of technology presenting at multiple conferences • Validated technology for routine use • ~1,000 plates per day at large AZ sites • >98% of plates are negative • Occasionally humans make mistakes • APAS resolves data integrity challenges Customer For personal use only
Page 11
Clever Culture Systems. ASX: CC5 11 Pharmaceutical manufacturing: Attractive market for optimisation Market For personal use only
Page 12
Clever Culture Systems ASX: CC5 12 3P System – bioMerieux (Interscience OEM) Growth Direct – Rapid Micro Biosystems (NASDAQ::RPID) APAS Independence: end point reader Different automation approach Incubation and reading technologies APAS delivers scale • 1 APAS instrument automates 1,600 plates per day • Customers use their existing low- cost, high-volume incubators 1. Daily capacity assumes industry standard 5-day incubation • Requires continuous reading between incubator and imaging platform • Incubation size restricts volume capacity (60-132 plates per day capacity) Incubator capacity ~660 plates ~132 plates per day1 Incubator capacity 300 plates ~60 plates per day1 Competition For personal use only
Page 13
Clever Culture Systems ASX: CC5 13 Europe: 17 instruments USA: 6 instruments Asia-Pac: 5 instruments Global footprint: 28 APAS® Independence instruments1 APAS sales APAS Training Hub Global pharma customer focus: AstraZeneca, Bristol Myers Squibb, Pfizer, Novo Nordisk, Boehringer Ingelheim, Patheon (Thermo Fisher) 1. Instruments sold & delivered, excludes evaluations and confirmed sales not installed (Feb-26) For personal use only
Page 14
Clever Culture Systems ASX: CC5 14 Brent Barnes CEO and MD, AU Aug-16 start • Board and Management shareholding 20%+ • International experience with healthcare, technology and pharmaceutical manufacturing expertise • Extensive public listed ASX experience in micro-cap and high-growth companies Rebecca Wilson Chair, AU Jul-23 start Ray Ridge CFO and CoSec, AU Dan Hill NED, AU Dec-23 start Board and Management Focused on expansion into pharmaceutical manufacturing industry Ian Wisenberg NED, US Oct-24 start Experienced For personal use only
Page 15
Clever Culture Systems. ASX: CC5 15 Growth in customer base New sales to global pharma companies Expected in H2 of FY26 and beyond Build customer expansion opportunity Support customer evaluations and establish trusted partnerships APAS® validated in routine use Growth in customers using the technology in routine operations Stable financial outlook Disciplined cashflow management, steady sales growing ARR Outlook For personal use only